If you are wondering whether Vertex Pharmaceuticals at around US$460 per share still lines up with its fundamentals, you are not alone. This article is here to unpack what that price might imply. The ...

Given the company's vast healthcare ecosystem, deep footprint across the U.S., and relationships with customers, CVS' ongoing ...

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 2.7% in that time frame, outperforming the S&P 500. But investors have to be ...

Vertex’s decision to double down on a pain program has delivered a phase 2 win. The biotech linked its NaV1.8 inhibitor VX-548 to statistically significant improvements in pain intensity in people ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

-Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with ...

Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings. But ...